Related Experiment Videos
Statin treatment withdrawal in ischemic stroke: a controlled randomized study.
M Blanco1, F Nombela, M Castellanos
1Department of Neurology, Hospital Clínico Universitario, Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Neurology
|August 29, 2007
Summary
Discontinuing statin therapy after an acute ischemic stroke significantly increases the risk of death or dependency. Continuing statin treatment during the acute phase is recommended for better patient outcomes.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Statins are known to mitigate brain injury in cerebral ischemia.
- This study investigates the impact of statin withdrawal versus continuation on acute ischemic stroke patient outcomes.
Purpose of the Study:
- To determine the effect of statin withdrawal on the outcomes of patients experiencing acute ischemic stroke.
- To compare outcomes between patients who continued statin therapy and those who had it withdrawn.
Main Methods:
- A randomized controlled study involving 89 patients with hemispheric ischemic stroke, divided into statin withdrawal or continuation groups.
- Primary outcome: death or dependency (modified Rankin Scale score > 2) at 3 months.
- Secondary outcomes: early neurologic deterioration and infarct volume.
Main Results:
- Statin withdrawal was linked to a higher rate of death or dependency (60.0% vs 39.0%) and increased early neurologic deterioration (65.2% vs 20.9%).
- Patients experiencing statin withdrawal had significantly larger infarct volumes compared to those continuing statins.
- Withdrawal increased the risk of death/dependency by 4.66-fold and early neurologic deterioration by 8.67-fold.
Conclusions:
- Statin withdrawal in the acute phase of ischemic stroke is associated with poorer outcomes, including increased mortality and dependency.
- Continuation of statin therapy is recommended for patients with acute ischemic stroke.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...